Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome

Every biological fluid, blood, interstitial fluid and lymph, urine, saliva, lacrimal fluid, nipple aspirate, and spinal fluid, contains a peptidome-degradome derived from the cellular secretome along with byproducts of the metabolic/ catabolic activities of each parenchymal organ. Clement et al. (J Proteomics 78: 172-187, 2013), Clement et al. (J Biol Chem 291: 5576-5595, 2016), Clement et al. (PLoS One 5:e9863, 2010), Clement et al. (Trends Immunol 32: 6-11, 2011), Clement et al. (Front Immunol 4: 424, 2013), Geho et al. (Curr Opin Chem Biol 10, 50-55, 2006), Interewicz et al. (Lymphology 37: 65-72, 2004), Leak et al. (Proteomics 4: 753-765, 2004), Popova et al. (PLoS One 9:e110873, 2014), Zhou et al. (Electrophoresis 25: 1289-1298, 2004), D'Alessandro et al. (Shock 42: 509-517, 2014), Dzieciatkowska et al. (Shock 42:485-498, 2014), Dzieciatkowska et al. (Shock 35:331-338, 2011), Jordan et al. (J Surg Res 143:130-135, 2007), Peltz et al. (Surgery 146:347-357, 2009), Zurawel et al. (Clin Proteomics 8:1, 2011), Ling et al. (Clin Proteomics 6:175-193, 2010), Sturm et al. (Nat Commun 4:1616, 2013). Over the last decade, qualitative and quantitative analysis of the biological fluids peptidome and degradome have provided a dynamic measurement of tissue homeostasis as well as the tissue response to pathological damage. Proteomic profiling has mapped several of the proteases and resulting degradation by-products derived from cell cycle progression, organ/tissue remodeling and cellular growth, physiological apoptosis, hemostasis, and angiogenesis. Currently, a growing interest lies in the degradome observed during pathological conditions such as cancer, autoimmune diseases, and immune responses to pathogens as a way to exploit biological fluids as liquid biopsies for biomarker discovery Dzieciatkowska et al. (Shock 42:485-498, 2014), Dzieciatkowska et al. (Shock 35:331-338, 2011), Ling et al. (Clin Proteomics 6: 175-193, 2010), Ugalde et al. (Methods Mol Biol 622:3-29, 2010), Quesada et al. (Nucleic Acids Res 37:D239-243, 2009), Cal et al. (Front Biosci 12, 4661-4669, 2007), Shen et al. (PLoS One 5:e13133, 2010a), Antwi et al. (Mol Immunol 46:2931-2937, 2009a), Antwi et al. (J Proteome Res 8:4722-4731, 2009b), Bedin et al. (J Cell Physiol 231, 915-925, 2016), Bery et al. (Clin Proteomics 11: 13, 2014), Bhalla et al. (Sci Rep 7: 1511, 2017), Fan et al. (Diagn Pathol 7: 45, 2012a), Fang et al. (Shock 34: 291-298, 2010), Fiedler et al. (Clin Cancer Res 15: 3812-3819, 2009), Fredolini et al. (AAPS J 12:504-518, 2010), Greening et al. (Enzymes 42: 27-64, 2017), He et al. (PLoS One 8: e63724, 2013), Huang et al. (Int J Gynecol Cancer 28:355-362, 2018), Hashiguchi et al. (Med Hypotheses 73: 760-763, 2009), Liotta and Petricoin (J Clin Invest 116: 26-30, 2006), Petricoin et al. (Nat Rev Cancer 6:961-967, 2006), Shen et al. (J Proteome Res 9:2339-2346, 2010a), Shen et al. (J Proteome Res 5:3154-3160, 2006), Smith (Clin Proteomics 11: 23, 2014), Wang et al. (Oncotarget 8:59376-59386, 2017), Yang et al. (Clin Exp Med 12:79-87, 2012a), Yang et al. (J Clin Lab Anal 26:148-154, 2012b), Yang et al. (Anat Rec (Hoboken) 293:2027-2033, 2010), Zapico-Muniz et al. (Pancreas 39:1293-1298, 2010), Villanueva et al. (Mol Cell Proteomics 5:1840-1852, 2006), Robbins et al. (J Clin Oncol 23:4835-4837, 2005), Klupczynska et al. (Int J Mol Sci 17: 410, 2016). In this review, we focus on the current knowledge of the degradome/peptidome observed in two main biological fluids (plasma and lymph) during physiological and pathological conditions and its importance for immune surveillance.